Why BioStem Technologies Chooses to Invest in Health Span Alternatives
05/03/2017 2:48 am EST
Sponsored Content—If you think there is no possibility for improving your health and extending your lifespan, then think again.
According to the National Institute on Aging, “On a global level, the 85-and-over population is projected to increase 351% between 2010 and 2050, compared to a 188% increase for the population aged 65 or older and a 22% increase for the population under age 65.”
There are many reasons why this rapid increase in life expectancy will continue. The fact of the matter is that we are all living longer and to enjoy those extra years it may require some extra effort.
But what do you do to maintain or improve your quality of life if your lifespan is increasing? Well, let’s leave that to the experts.
Personally, I have found the BioStem Wellness/Dr. Dave’s Best supplement lines encompass some of what the aging body needs. From the highest quality, sustainably sourced Ultra 85 fish oil produced under pharmaceutical manufacturing standards to the Telomere Edge Packs to Sleep Wizard, all the products have been designed by doctors specifically for curbing the body’s natural aging process. These products have been co-developed and acquired by BioStem Technologies to advance anti-aging and regenerative medicine a leap ahead.
Additionally, the company has covered the gamut when it comes to the Biotechnology and Regenerative Medicine Sectors. Starting a little under three years ago with a different approach, BioStem Technologies, Inc. (BSEM) has some exciting news for investors, partners and customers. The company will uplist on an exchange and improve financial reporting.
What BSEM has done is combine Pharmaceuticals, Nutraceuticals, Stem Cell Science and Blue and Green Technologies under one publicly traded corporation. This approach has led to over seven acquisitions, the recent completion of the Pharmaceutical Manufacturing and Stem Cell Research Laboratory, as well as the issuance securing state and FDA establishment licenses.
My final point: BioStem Technologies not only has the ability of “using Mother Nature to beat Father Time,” as the wellness products package states, but it could benefit your financial portfolio as well.
The company is currently undergoing a $6,000,000 private placement. Upon review of its PPM, the company is ready for exponential expansion and penetration into some of the highest grossing international markets. These include pharmaceutical production and development, sales of active pharmaceutical ingredients, and 503b sterile manufacturing.
According to the most recent filing, the company has around 3.6 million shares issued/outstanding and has been trading around $9 per share with 223 shareholders of record. With the recent announcement of soon to be audited financials and plans to uplist, BioStem Technologies, Inc. is poised for a major acquisition or development projects in the near future.
For more information about BioStem Technologies, Inc., contact: